J&J Says New Model-Based Analysis Further Supports The Potential Of Tecvayli Plus Darzalex Faspro
JNJ•New model-based analysis supports Tecvayli plus Darzalex Faspro
Sept. 23 (Reuters) - Johnson & Johnson (JNJ.N):
- New model-based analysis further supports the potential of Tecvayli (teclistamab-cqyv) plus Darzalex Faspro (daratumumab and hyaluronidase-fihj) to redefine long-term survival expectations in early line relapsed/refractory multiple myeloma.
- J&J said the analysis estimates 87% of Tecvayli plus Darzalex Faspro patients have comparable mortality risk to the general population.
- J&J said Tecvayli plus Darzalex Faspro reduces multiple myeloma progression risk by 90% versus standard of care.
Source text: ID:nPnbHbsDHa
Further company coverage: JNJ.N
